dociparstat + chemotherapy

**Dociparstat + chemotherapy** is a combination therapeutic regimen under investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Dociparstat sodium (DSTAT, CX-01) is a low-anticoagulant heparin derivative with robust anti-inflammatory and anti-coagulant properties. Its mechanisms include inhibition of the CXCR4/CXCL12 axis (reducing leukemia stem cell homing and protection), blockade of high-mobility group box 1 (HMGB1), and binding/inhibition of platelet factor 4 (PF4). In clinical studies, dociparstat is combined with standard induction chemotherapy agents (idarubicin, daunorubicin, cytarabine) or azacitidine to potentially improve remission rates and hematologic recovery, aiming to reduce chemotherapy-related cytopenias and enhance overall survival in relapsed/refractory and newly diagnosed AML/MDS[1][3][5]. Dociparstat is under clinical development, typically administered by intravenous infusion alongside standard chemotherapeutic regimens.

Other names

dociparstat sodium + chemotherapydociparstat sodium + idarubicin/daunorubicin/cytarabinedociparstat sodium + azacitidine